PT  - JOURNAL ARTICLE
AU  - Rana, Vishal
AU  - Chien, Eli
AU  - Peng, Jianhao
AU  - Milenkovic, Olgica
TI  - Small-sample estimation of the mutational support and the distribution of mutations in the SARS-Cov-2 genome
AID  - 10.1101/2020.04.23.20076075
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.04.23.20076075
4099  - http://medrxiv.org/content/early/2021/04/26/2020.04.23.20076075.short
4100  - http://medrxiv.org/content/early/2021/04/26/2020.04.23.20076075.full
AB  - The problem of estimating unknown features of viral species using a limited collection of observations is of great relevance in computational biology. We consider one such particular problem, concerned with determining the mutational support and distribution of the SARS-Cov-2 viral genome and its open reading frames (ORFs). The mutational support refers to the unknown number of sites that is expected to be eventually mutated in the SARS-Cov-2 genome. It may be used to assess the virulence of the virus or guide primer selection for real-time RT-PCR tests during the early stages of an outbreak. Estimating the unknown distribution of mutations in the genome of different subpopulations while accounting for the unseen may aid in discovering adaptation mechanisms used by the virus to evade the immune system. To estimate the mutational support in the small-sample regime, we use GISAID sequencing data and new state-of-the-art polynomial estimation techniques based on weighted and regularized Chebyshev approximations. For distribution estimation, we adapt the well-known Good-Turing estimator. We also perform a differential analysis of mutations and their sites across different populations. Our analysis reveals several findings: First, the mutational supports exhibit significant differences in the ORF6 and ORF7a regions (older vs younger patients), ORF1b and ORF10 regions (females vs males) and as may be expected, in almost all ORFs (for Asia versus Europe and North America). Second, despite the fact that the N region of SARS-Cov-2 has a predicted 10% mutational support, almost all observed mutations fall outside of the two regions of paired primers recommended for testing by the CDC.Author Summary We introduce the new problem of small-sample estimation of the number of mutations and the distribution of mutations in viral and bacterial genomes, and in particular, in the SARS-Cov-2 genome. The approach is of interest due to the fact that it aims to predict which regions in the genome will mutate in the future and with what frequency, given only a very limited number of complete viral sequences. This setting is usually encountered during the early stages of an outbreak when it is critical to assess the potential of the virus to gain mutations advantageous for its spreading. The results may also be used to guide the selection of genomic (primer) regions that are not subject to mutational pressure and can consequently be used as identifiers in the process of testing for the disease. They can also highlight differences in the mutation rates and locations of the SARS-Cov-2 virus affecting diverse subpopulations and therefore potentially suggest the role of certain mutations in evading the immune system. Our approach uses a new class of estimation methods that may find other applications in bioinformatics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCenter for Computational Biotechnology and Genomic Medicine, NSF IUCRC Award number 1624790 Emerging Frontiers of Science of Information, NSF STC, Award number 0939370Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work does not involve any clinical trails or patient informations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequencing data we used is available from GISAID under hCoV-19 https://www.gisaid.org/